Advisory Committee
Prof. Dean Fennell
http://www2.le.ac.uk/departments/csmm/people/professor-dean-fennell
Professor Dean FennellChair of Thoracic Medical Oncology,
Cancer Research UK Centre Leicester, University of Leicester and University Hospitals of Leicester NHS Trust
I'm the current president of the International Mesothelioma interest group, co-chairing the global meeting in the UK in 2016. I was also a planning committee member of the 2016 International Association for the Study of Lung Cancer (IASLC) world lung cancer conference. I have writen more than 100 publications in journals including Lancet, Lancet Oncology, Proceedings of the National Academy of Science, Nature Communications and Journal of the National Cancer Institute.Contact details
- Tel: 0116 258 7603
- Email: DF132@le.ac.uk,
- Office: Level 2, Osborne Building, Leicester Royal Infirmary, Leicester Royal Infirmary, and Laboratory 411, 4th Floor, Hodgkin Building.
Prof. Peter Szlosarek
http://www.bci.qmul.ac.uk/staff/item/peter-szlosarek
Dr Peter SzlosarekMD, PhD
Centre: Molecular Oncology
Reader in Medical Oncology
p.w.szlosarek@qmul.ac.uk
QMUL Directory
My main research interest is in exploring why argininosuccinate synthetase (ASS1), a rate-limiting enzyme in L-arginine synthesis, is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy.
I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers including ADAM, TRAP and ATOMIC clinical studies.
http://www.bci.qmul.ac.uk/staff/item/peter-szlosarek
Dr Peter SzlosarekMD, PhD
Centre: Molecular Oncology
Reader in Medical Oncology
p.w.szlosarek@qmul.ac.uk
QMUL Directory
My main research interest is in exploring why argininosuccinate synthetase (ASS1), a rate-limiting enzyme in L-arginine synthesis, is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy.
I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers including ADAM, TRAP and ATOMIC clinical studies.
|
|
|
